By PPN Staff
The FDA granted a new indication for dupilumab (Dupixent, Sanofi/Regeneron) to treat adults with prurigo nodularis. The medication is the first FDA-approved treatment for this chronic skin disease.
The new indication is based on data from the phase 3, placebo-controlled PRIME and PRIME2 trials. Participants received 300 mg of dupilumab every two weeks following an initial dose of 600 mg.
By week 24 in the trials, 60% and 58% of patients in the dupilumab groups experienced a reduction